Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACRE-2: SCRT +/- FOLFOX4s in Elderly Patients with Locally Advanced Rectal Cancer
NCT07118800Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Primary completion
- Dec 2030
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, folinic acid and fluorouracil in rectal cancer (2 arms), sponsored by Unicancer. Primary endpoint: Total Mesorectal Excision-free survival at 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07118800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118800.